Vir Biotechnology, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vir Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.36M, a 22.82% decline year-over-year.
- Vir Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $1.04M, a 10.42% decline year-over-year.
- Vir Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- Vir Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $1.76M, a 32.48% decline year-over-year.
- Vir Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $2.80M, a 25.67% decline from fiscal 2024.
- Vir Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $3.76M, a 12.14% decline from fiscal 2023.
- Vir Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $4.28M, a 32.93% increase from fiscal 2022.
- Vir Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $3.22M, a 40.09% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $1.36M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.80M 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | |
| 2025-06-30 | $1.76M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.76M 10-K · filed 2026-02-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | |
| 2024-06-30 | $2.60M 10-Q · filed 2025-08-06 | |
| 2023-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $4.28M 10-K · filed 2026-02-23 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | |
| 2023-06-30 | $2.60M 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.22M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | |
| 2022-06-30 | $2.07M 10-Q · filed 2023-08-04 | |
| 2021-12-31 | $2.30M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |